In summary, the key findings from the present study suggested that dehydrovomifoliol potentially alleviates NAFLD through disruption of the E2F1/AKT/mTOR axis (Figure 8). This evidence concerns the gene E2F1 and metabolic dysfunction-associated steatotic liver disease.